← Companies
Sponsor / Institution
Sunnybrook Health Sciences Centre
Organization-level profile for a sponsor, institution, collaborator, or mixed-role entity. These profiles are separated from the primary industry company index when appropriate.
Programs
2
linked to organization
Strong Evidence
0
0 status confirmed
Details Checked
2
0 open data checks
Company / Institution Links
0 / 2
industry vs non-industry records
Competitive Density
3
Pipeline Velocity
50
Completion Signal
50
Programs by Stage
Phase 21
Phase 41
Trial / Program Status
Active1
Unknown1
Modality Mix
Small Molecule2
Indication Coverage
Cisplatin-Induced Hearing Loss2
Hearing Loss2
Ototoxicity1
Sensorineural Hearing Loss1
Tinnitus1
Program Types
Therapeutic2
Population Tags
adult2
cisplatin-ototoxicity2
bilateral1
cancer1
otoprotection1
tinnitus1
Strong-Evidence Records
0 recordsNo strong-evidence records are linked to this organization yet.
Checked Records With Caveats
2 checked · 0 open checksIntratympanic N-Acetylcysteine Cisplatin Otoprotection Studies
Details checked
Small MoleculePhase 4Unknown
Registry-backed institution-led studies evaluating intratympanic N-acetylcysteine before cisplatin chemotherapy to prevent or reduce cisplatin-induced ototoxic hearing loss.
Data checks: institution-led-study, registry-only-evidence
Sunnybrook sodium thiosulfate plus mannitol cisplatin otoprotection study
Details checked
Small MoleculePhase 2Active
Intravenous sodium thiosulfate plus mannitol administered 4-8 hours after cisplatin chemotherapy to reduce adult cisplatin-induced ototoxic hearing loss.
Data checks: institution-led-study, active-recruiting